Yale Spinout Estuary Biotherapeutics Launches with $103 Million to Develop Gene Therapies for Polycystic Kidney Disease
Editor’s Note: Estuary Biotherapeutics was founded on research from Stefan Somlo, MD, C.N.H. Long Professor of Medicine and Genetics and Professor of Nephrology, and Michael Caplan, MD, PhD, C.N.H. Long Professor and Chair of Cellular and Molecular Physiology, both at Yale School of Medicine. This release is reposted courtesy of Estuary Biotherapeutics.
Estuary Biotherapeutics Launches with $103 Million to Develop Targeted Gene Therapies for Kidney Disease
Paradigm-shifting approach targeting the root cause of autosomal dominant polycystic kidney disease (ADPKD), with the goal of durably halting or reversing the structural and functional manifestations of the disease
Proceeds to advance lead programs targeting the two most common genetic subtypes of ADPKD through clinical proof of concept and to support broader pipeline expansion
Company launches with world-class management team, board of directors and advisers, backed by leading healthcare investors
MENLO PARK, Calif., and NEWTON, Mass., October 16, 2026 – Estuary Biotherapeutics, Inc., a biotechnology company developing genetic medicines for patients with serious kidney diseases, today announced its launch with $103 million in total committed financing.
“ADPKD is one of the world’s most common genetic diseases, yet patients are still awaiting a therapy that can transform the course of their disease,” said Wayne Sackett, co-founder and CEO of Estuary. “We paired our scientific co-founders’ landmark breakthroughs in disease biology with a dedicated and passionate team focused on solving the most crucial remaining barrier to kidney gene therapy: delivery. By pioneering fit-for-purpose local administration and an efficient global development strategy, our team is moving with urgency to bring these important medicines into the clinic.”